| 000 -LEADER |
|---|
| fixed length control field |
01825nab a2200301 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
190612b2019 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Deo A |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2019 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
|
| 500 ## - GENERAL NOTE |
|---|
| General note |
Address for correspondence: pray@actrec.gov.in |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
Aim: To evaluate the potential of IGF1R as a prognostic marker for high-grade serous ovarian cancer (HGSOC) patients. Patients & methods: The expression levels of IGF1R and drug transporters (ABCB1, hCtr1) were measured longitudinally in chemo-naive and chemo-treated tumor samples from 19 HGSOC patients, and their correlation with the clinical outcome was examined. Results: IGF1R expression was significantly upregulated in treated tumor samples, which positively correlated with hCtr1 levels. Patients with metastatic tumors with IGF1R expression higher than median showed better overall survival (median not reached) and disease-free survival (26.7 months) than those with less than median expression (overall survival: 27.5 months [p = 0.029]; disease-free survival: 11.9 months [p = 0.014]). Conclusion: IGF1R prognosticates prolonged survival in HGSOC patients, possibly due to its positive correlation with hCtr1. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
HGSOC |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
IGF1R |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
hCtr1 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Neoadjuvant chemotherapy |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Ovarian cancer |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Prognostic marker |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Chaudhury S |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kannan S |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Rekhi B |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Maheshwari A |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Gupta S |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ray P |
| 773 ## - HOST ITEM ENTRY |
|---|
| Main entry heading |
Biomarkers in Medicine |
| Place, publisher, and date of publication |
London : Future Medicine, 2019 |
| Relationship information |
Vol. 13, no. 07, p. 511-521. |
| International Standard Serial Number |
1752-0363 |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| Dept |
Pathology |
| Corporate name |
TMC |
| PMID |
31140856 |
| Article Type |
Journal Article |
| Country type |
International |
| Added Entry |
TMH |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
Articles |
